Parkinson's Disease (PD)NCT07308418
The Influence of Vibrotactile Stimulation on Self-selected Walking Speed in People With Parkinson's Disease
A study testing Vibrotactile feedback during walking in people with Parkinson's Disease (PD), run by Magnes AG at 1 site in Switzerland.
Trial summary
The study tests whether a smart shoe (NUSHU) that provides vibrotactile stimulation can improve walking speed in people with Parkinson's disease. Sixteen participants complete two short walking tests-with and without vibration-to compare gait speed, cadence, stride length, usability, and safety. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Parkinson's Disease (PD)
- What is being tested?
- Vibrotactile feedback during walking
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteSwitzerland
- Study dates
- 10 Jan 2026to 18 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- A medically confirmed diagnosis of Parkinson's disease on the physiotherapy prescription.
- Stable medication for at least four weeks (no change in dopaminergic therapy).
- The ability to walk at least 200 metres without stopping.
- Minimum age: 18 years
- Sufficient knowledge of German to understand the study information and complete the questionnaires.
- Written informed consent form
Who cannot join
- Atypical or secondary Parkinsonism
- Sensory disturbances in the feet (e.g. polyneuropathy).
- Other neurological, orthopaedic or internal medical conditions that significantly affect walking
- Cognitive impairments that interfere with understanding the study information or following instructions
Trial locations and contacts
1 site in 1 country.
About this study
The study tests whether a smart shoe (NUSHU) that provides vibrotactile stimulation can improve walking speed in people with Parkinson's disease. Sixteen participants complete two short walking tests-with and without vibration-to compare gait speed, cadence, stride length, usability, and safety. It is a low-risk pilot study meant to generate first evidence for future research.
Read the detailed description
Study Overview
This monozentric, prospective within-subject crossover pilot study investigates whether vibrotactile stimulation provided by the NUSHU, a CE-certified smart shoe, can influence spatiotemporal gait parameters-primarily self-selected walking speed-in adults with Parkinson's disease (PD). Parkinson's disease is often associated with reduced gait speed, shorter strides, and altered cadence, all of which are clinically relevant because they correlate with morbidity, fall risk, and quality of life.
Rationale
Earlier research suggests that vibration can positively influence gait by modulating proprioception, but existing devices have been impractical or clinically cumbersome. The NUSHU integrates sensors and vibration modules into an everyday shoe, enabling precise, phase-specific stimulation during the swing phase. Since no previous PD studies have tested this device, the project seeks to assess feasibility, safety, and initial efficacy signals.
Participants
Sixteen adults with a confirmed Parkinson's diagnosis will be recruited from multiple Physiozentrum Zürich locations. Key inclusion requirements include stable medication, ability to walk ≥ 200 m without resting, and sufficient understanding of German. Exclusion criteria include neuropathy, atypical parkinsonism, major comorbid gait disorders, or cognitive impairment that may interfere with procedures.
Study Design and Procedures
Participants attend a single 45-minute session consisting of:
Informed consent and eligibility assessment
Instruction on NUSHU use
Two 2-minute walking tests (with and without vibration), in randomized order
A 15-minute washout between tests
Completion of the System-Usability-Scale (SUS) questionnaire
Continuous monitoring and documentation of safety events and perceived stability
The assessor is blinded regarding the stimulation condition to reduce bias.
Outcomes
Primary outcome:
Difference in self-selected gait speed between vibration vs. no-vibration conditions.
Secondary outcomes:
- Cadence
- Stride length
- Usability (SUS-DE)
- Safety observations and subjective stability ratings
Statistics As an exploratory pilot, the study is not powered for confirmatory conclusions. Paired statistical tests (t-test or Wilcoxon) will evaluate within-subject differences. Descriptive methods and Bonferroni-corrected secondary analyses will complement the primary evaluation.
Ethics \& Risk Classified as Risk Category A, the study involves minimal risk, mainly the normal risk associated with walking. Strict inclusion criteria and supervised testing aim to reduce fall risk. Data will be pseudonymized and securely stored. Although participants receive no direct clinical benefit, the findings will support future research on technology-assisted mobility strategies for PD.
Purpose:
- Overall, the study aims to understand:
- The short-term effect of vibrotactile stimulation on gait
- The feasibility, usability, and safety of NUSHU in a PD population
- Whether larger, controlled trials are justified
- Conditions
- Parkinson's Disease (PD)
- Being tested
- Vibrotactile feedback during walking
- Keywords
- Parkinson's Disease, Gait analysis, Vibrotactile feedback
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vibrotactile feedback during walkingDevice
NUSHU smart shoes give real time gait feedback during walking.
| Study group | Role | What they receive |
|---|---|---|
| Vibrotactile feedback while walking | Active comparator | Not described Receives: Device: Vibrotactile feedback during walking |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in self-selected walking speed (m/s)
Change in self-selected walking speed (m/s), measured over a 2-minute walking test with and without stimulation by the NUSHU. Walking speed is measured in m/s as a continuous metric variable, which is an objective and established way of measuring walking speed. The calculation is performed by dividing the total distance covered by the time in seconds (120 seconds).
Measured: Once during 120 seconds
Change in self-selected gait speed
Measured: One visit of 45 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2025
- Study start10 Jan 2026
- Primary completion18 Mar 2026
- Study completion18 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson's Disease (PD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Magnes AG
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07308418
- Sponsor's protocol ID
- 2025-01560
- Other IDs
- 2025
- Status last verified
- Feb 2026
- First submitted
- 1 Dec 2025
- Last updated
- 6 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Influence of Vibrotactile Stimulation on Self-selected Walking Speed in People With Parkinson's Disease
- ClinicalTrials.gov ID
- NCT07308418
- Acronym / sponsor ID
- 2025-01560
- Conditions
- Parkinson's Disease (PD)
- Keywords
- Parkinson's Disease, Gait analysis, Vibrotactile feedback
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Magnes AGIndustry (pharma, biotech, devices)
- Study start
- 10 Jan 2026 (actual)
- Primary completion
- 18 Mar 2026 (actual)
- Study completion
- 18 Mar 2026 (actual)
- First posted
- 29 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study tests whether a smart shoe (NUSHU) that provides vibrotactile stimulation can improve walking speed in people with Parkinson's disease. Sixteen participants complete two short walking tests-with and without vibration-to compare gait speed, cadence, stride length, usability, and safety. It is a low-risk pilot study meant to generate first evidence for future research.
Detailed description
Study Overview
This monozentric, prospective within-subject crossover pilot study investigates whether vibrotactile stimulation provided by the NUSHU, a CE-certified smart shoe, can influence spatiotemporal gait parameters-primarily self-selected walking speed-in adults with Parkinson's disease (PD). Parkinson's disease is often associated with reduced gait speed, shorter strides, and altered cadence, all of which are clinically relevant because they correlate with morbidity, fall risk, and quality of life.
Rationale
Earlier research suggests that vibration can positively influence gait by modulating proprioception, but existing devices have been impractical or clinically cumbersome. The NUSHU integrates sensors and vibration modules into an everyday shoe, enabling precise, phase-specific stimulation during the swing phase. Since no previous PD studies have tested this device, the project seeks to assess feasibility, safety, and initial efficacy signals.
Participants
Sixteen adults with a confirmed Parkinson's diagnosis will be recruited from multiple Physiozentrum Zürich locations. Key inclusion requirements include stable medication, ability to walk ≥ 200 m without resting, and sufficient understanding of German. Exclusion criteria include neuropathy, atypical parkinsonism, major comorbid gait disorders, or cognitive impairment that may interfere with procedures.
Study Design and Procedures
Participants attend a single 45-minute session consisting of:
Informed consent and eligibility assessment
Instruction on NUSHU use
Two 2-minute walking tests (with and without vibration), in randomized order
A 15-minute washout between tests
Completion of the System-Usability-Scale (SUS) questionnaire
Continuous monitoring and documentation of safety events and perceived stability
The assessor is blinded regarding the stimulation condition to reduce bias.
Outcomes
Primary outcome:
Difference in self-selected gait speed between vibration vs. no-vibration conditions.
Secondary outcomes:
- Cadence
- Stride length
- Usability (SUS-DE)
- Safety observations and subjective stability ratings
Statistics As an exploratory pilot, the study is not powered for confirmatory conclusions. Paired statistical tests (t-test or Wilcoxon) will evaluate within-subject differences. Descriptive methods and Bonferroni-corrected secondary analyses will complement the primary evaluation.
Ethics \& Risk Classified as Risk Category A, the study involves minimal risk, mainly the normal risk associated with walking. Strict inclusion criteria and supervised testing aim to reduce fall risk. Data will be pseudonymized and securely stored. Although participants receive no direct clinical benefit, the findings will support future research on technology-assisted mobility strategies for PD.
Purpose:
- Overall, the study aims to understand:
- The short-term effect of vibrotactile stimulation on gait
- The feasibility, usability, and safety of NUSHU in a PD population
- Whether larger, controlled trials are justified
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Vibrotactile feedback while walking | Active comparator | Device: Vibrotactile feedback during walking |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- A medically confirmed diagnosis of Parkinson's disease on the physiotherapy prescription.
- Stable medication for at least four weeks (no change in dopaminergic therapy).
- The ability to walk at least 200 metres without stopping.
- Minimum age: 18 years
- Sufficient knowledge of German to understand the study information and complete the questionnaires.
Key exclusion criteria (4 listed)
- Atypical or secondary Parkinsonism
- Sensory disturbances in the feet (e.g. polyneuropathy).
- Other neurological, orthopaedic or internal medical conditions that significantly affect walking
- Cognitive impairments that interfere with understanding the study information or following instructions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vibrotactile feedback during walkingNUSHU smart shoes give real time gait feedback during walking. | Device | Vibrotactile feedback while walking |
Primary outcome
Change in self-selected walking speed (m/s)
Time frame: Once during 120 seconds
Change in self-selected walking speed (m/s), measured over a 2-minute walking test with and without stimulation by the NUSHU. Walking speed is measured in m/s as a continuous metric variable, which is an objective and established way of measuring walking speed. The calculation is performed by dividing the total distance covered by the time in seconds (120 seconds).
Change in self-selected gait speed
Time frame: One visit of 45 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Parkinson's Disease (PD)
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
RecruitingObservational study
Parkinson's Disease in Type 1 Gaucher Disease
Parkinson Disease (PD), Type 1 Gaucher Disease
Not yet recruitingPhase 1
AAV2-hAADC for Parkinson's Disease (PDCS-01)
Parkinson's Disease (PD), Early Onset Parkinson Disease
Recruiting
Effects of Microelectrode-based Brain Stimulation in Humans
Essential Tremor, Parkinsons Disease (PD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vibrotactile feedback during walking in people with Parkinson's Disease (PD), run by Magnes AG at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in self-selected walking speed (m/s) (time frame: Once during 120 seconds). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026; AzTrials last refreshed its copy on 7 Nov 2026.